comparemela.com
Home
Live Updates
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgens CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers : comparemela.com
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers
SHANGHAI, May 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell the...
Related Keywords
China ,
Beijing ,
Shanghai ,
United States ,
Canada ,
Lin Shen ,
Guangdong ,
America ,
Zonghai Li ,
Carsgen Therapeutics Holdings ,
Prnewswire Carsgen Therapeutics Holdings Limited Stock Code ,
Health Canada ,
Therapeutics Holdings Limited ,
Stock Code ,
Nature Medicine ,
Nature Portfolio ,
Impact Factor ,
Professor Lin Shen ,
Beijing Cancer Hospital ,
Chief Executive Officer ,
Chief Scientific Officer ,
North America ,
Orphan Drug ,
Orphan Medicinal Product ,
Regenerative Medicine Advanced Therapy ,
Therapeutics Holdings ,
comparemela.com © 2020. All Rights Reserved.